TOP2A
TOP2A (DNA topoisomerase II alpha, also known as TOP2alpha, TOPIIA and TOP2) is a nuclear type II topoisomerase that alters DNA topology by passing one double-stranded DNA segment through a transient break in another. It acts as a key decatenating enzyme. Browse Assay Genie's current range of TOP2A research reagents below, or read on for the biology behind the target.
TOP2A is a key decatenating enzyme that alters DNA topology. It binds two double-stranded DNA molecules, generates a double-stranded break in one of them, passes the intact strand through the break and then religates the broken strand. This transient breaking and rejoining of duplex DNA allows strands to pass through one another, controlling the topological state of DNA during transcription and replication. UniProt also notes that the protein may play a role in regulating the period length of BMAL1 transcriptional oscillation.
The TOP2A gene encodes the alpha form of DNA topoisomerase II and belongs to the type II topoisomerase family, listed by HGNC in the topoisomerases gene group. The enzyme is classified as EC 5.6.2.2. It is described as a nuclear enzyme, and UniProt records localisation to the nucleoplasm and nucleolus as well as the cytoplasm. NCBI Gene describes its involvement in chromosome condensation, chromatid separation and the relief of torsional stress that arises during DNA transcription and replication.
Two forms of the enzyme exist, likely products of a gene duplication event: the alpha form encoded by TOP2A on chromosome 17 and the beta form encoded by TOP2B on chromosome 3. The previous HGNC name for the gene was topoisomerase (DNA) II alpha 170kDa. TOP2A is the target of several anticancer agents, and a variety of mutations in the gene have been associated with the development of drug resistance. Reduced activity of this enzyme may also play a role in ataxia-telangiectasia. Mouse and rat both carry a Top2a ortholog.
TOP2A is the target of several anticancer agents, and mutations in the gene have been associated with the development of drug resistance.
The enzyme is involved in chromosome condensation and chromatid separation, and acts as a key decatenating enzyme.
TOP2A relieves the torsional stress that arises during DNA transcription and replication by transiently breaking and rejoining duplex DNA.
UniProt reports that TOP2A may play a role in regulating the period length of BMAL1 transcriptional oscillation.
TOP2A is a type II topoisomerase and key decatenating enzyme. It binds two double-stranded DNA molecules, makes a double-strand break in one, passes the intact strand through the gap and religates it. This changes DNA topology during transcription, replication, chromosome condensation and chromatid separation.
The HGNC-approved name is DNA topoisomerase II alpha, and UniProt uses DNA topoisomerase 2-alpha. Aliases and previous symbols include TOP2alpha, TOPIIA and TOP2. An earlier gene name was topoisomerase (DNA) II alpha 170kDa. The enzyme is classified as EC 5.6.2.2.
TOP2A and TOP2B are the alpha and beta forms of topoisomerase II, likely arising from a gene duplication, and are encoded on chromosomes 17 and 3 respectively. TOP2A is an anticancer drug target, with mutations linked to drug resistance, and reduced activity may play a role in ataxia-telangiectasia.
Other DNA topoisomerases, including the beta form of topoisomerase II and type I and type III enzymes, with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P11388; product specifications from Assay Genie datasheets.